FDA Offers Draft Guidance for Developing Abuse-Deterrent Opioids

Washington Drug Letter
Drug manufacturers developing opioids with abuse-deterrent properties should use three categories of premarket studies to provide enough data on a drug’s prospects for reducing abuse or misuse, according to new draft FDA guidance.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00